Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Align TechnologyXTER:AFW -3.09%89 Debt-to-EBITDA is 0.13 as of Mar. 2026, which is 13% below its 10-year median of 0.15. GuruFocus rates XTER:AFW with a GF Score™ of 89/100 and a GF Value™ of €214.27 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Align Technology ranks better than 88.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Align Technology's Debt-to-EBITDA or its related term are showing as below:
XTER:AFW'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1 Med: 0.15 Max: 0.18
Current: 0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Align Technology was 0.18. The lowest was 0.10. And the median was 0.15.
XTER:AFW's Debt-to-EBITDA is ranked better than 88.44% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs XTER:AFW: 0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Align Technology Debt-to-EBITDA Related Terms
Align Technology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Align Technology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AFW vs BAX, SOLV, COO: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Align Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Align Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Align Technology (XTER:AFW) has a Debt-to-EBITDA of 0.13 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Align Technology. This is 13% below median its historical median of 0.15. Over the past decade, Align Technology's Debt-to-EBITDA has ranged from 0.10 to 0.18. According to the industry distribution chart, Align Technology ranks #54 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is Align Technology's Debt-to-EBITDA too high?
Align Technology's current Debt-to-EBITDA of 0.13 is 13% below median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.18. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Align Technology's value of 0.13 is 91.9% below this industry median. Based on the distribution chart, Align Technology ranks #54 out of 467 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Align Technology has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's Debt-to-EBITDA compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Align Technology ranks #54 out of 467 companies for Debt-to-EBITDA. This places Align Technology in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.60. Align Technology's value of 0.13 is 91.9% below this benchmark. Historically, Align Technology's own Debt-to-EBITDA has ranged from 0.10 to 0.18 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 1.60, Align Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Align Technology's current Debt-to-EBITDA of 0.13 is 91.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Align Technology. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Align Technology's current Debt-to-EBITDA is 0.13, which is 13% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Significantly Undervalued. The stock's GF Value™ is €214.27, compared to a current price of €148.90 — trading 30.5% below its estimated fair value. The current Debt-to-EBITDA is 0.13, which is 13% below median its 10-year median of 0.15 and 91.9% below the Medical Devices & Instruments industry median of 1.60. Align Technology's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current Debt-to-EBITDA is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Align Technology (XTER:AFW) Overvalued in 2026?
Based on GuruFocus' analysis, Align Technology stock appears to be undervalued.
The current stock price of €148.90 is trading 30.5% below its estimated GF Value™ of €214.27.
GuruFocus considers Align Technology to be Significantly Undervalued.
Key valuation signals for XTER:AFW:
Debt-to-EBITDA: 0.13 (13% below median its 10-year median of 0.15)
GF Value™: €214.27 vs. price of €148.90 (30.5% below fair value)
Industry Position: 91.9% below the Medical Devices & Instruments median (#54 of 467)
No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
89GF Score
Get the complete analysis for XTER:AFW
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AFW has been successfully added to your 
